Catecholamines: Knowledge and understanding in the 1960s, now, and in the future (original) (raw)
Preface. The Tenth International Catecholamine Symposium (XICS)
Lee Eiden
Advances in pharmacology (San Diego, Calif.), 2013
View PDFchevron_right
Catecholamine Research in the 21ST Century
Ricardo Borges
View PDFchevron_right
Catecholamine metabolism and psychiatric or behavioral disorders
Claudine Laurent
Current Opinion in Genetics & Development, 1994
View PDFchevron_right
Compartmentation of catecholamines in rat brain: Effects of agonists and antagonists
Angelos Halaris
Brain Research, 1980
View PDFchevron_right
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Graeme Eisenhofer
Pharmacological Reviews, 2004
View PDFchevron_right
Pharmacology and psychiatry
Edwin Marley
Psychological Medicine, 1972
View PDFchevron_right
The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat
Christian Pifl
European Journal of Pharmacology, 1988
View PDFchevron_right
Collaborative psychopharmacologic studies exploring catecholamine metabolism in psychiatric disorders
Sherwin Wilk
Biochemical Pharmacology, 1974
View PDFchevron_right
Affective disorders: The catecholamine hypothesis revisited
Frederick Goodwin
Biochemical Pharmacology, 1974
View PDFchevron_right
Long-term application of some catecholamines elevates levels of other catecholamines in rats
Anton Sadjak
Experimental pathology, 1985
View PDFchevron_right
Effects of some antipsychotic drugs on cardiovascular catecholamine receptors in the rat
Elisabet Vila Calsina
Journal of Autonomic Pharmacology, 1989
View PDFchevron_right
Both α- and β-adrenoceptors contribute to the central depressor effect of catecholamines
Che-Se Tung
Brain Research, 1988
View PDFchevron_right
The effect of neuroleptics on the activity of central catecholamine neurones
Kjell Fuxe
Life Sciences - LIFE SCI, 1967
View PDFchevron_right
High concentrations of catecholamines in human hypothalamic-hypophysial blood
roberto paradisi
Journal of Clinical Investigation, 1989
View PDFchevron_right
The 5-hydroxytryptamine2 agonist, (±)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration
Charles Nemeroff
Journal of Pharmacology and Experimental Therapeutics
View PDFchevron_right
The interaction between different metabolic pathways of catecholamines in the brain studied by means of 3H-DOPA
Tobias Persson
Acta pharmacologica et toxicologica, 1969
View PDFchevron_right
Bozarth Dopamine 2017 preprint
Michael Bozarth
View PDFchevron_right
Pharmacological analysis of the neurotransmitter mechanisms regulating phenylethanolamine N-methyltransferase in the adrenal gland
Lívia Lima
Biochemical Pharmacology, 1986
View PDFchevron_right
Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action
A. Greenshaw
Progress in neuro-psychopharmacology & biological psychiatry, 1989
View PDFchevron_right
Neurobiology and neuropharmacology of monoaminergic systems
Rona Ramsay
Progress in Neurobiology, 2017
View PDFchevron_right
Purinergic regulation of brain catecholamine neurotransmission: In vivo electrophysiology and microdialysis study in rats
Eliyahu Dremencov
General Physiology and Biophysics, 2017
View PDFchevron_right
Adrenaline and Noradrenaline: Partners and Actors in the Same Play
Rui Carvalho
Neuroscience - Dealing With Frontiers, 2012
View PDFchevron_right
On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?
Giovanna Flore
Current Neuropharmacology, 2006
View PDFchevron_right
Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats
Natasa Spasojevic
PubMed, 2007
View PDFchevron_right
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions
Vincenza D'Angelo
Frontiers in Aging Neuroscience, 2015
View PDFchevron_right
Dopamine receptorsâphysiological understanding to therapeutic intervention potential
Stephanie Cragg
Pharmacology & Therapeutics, 1999
View PDFchevron_right
Brain Norepinephrine: Neurobiology and Therapeutics
Michael A Schwartz, G. Ordway
View PDFchevron_right
Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization
George Aghajanian
European Journal of Pharmacology, 1977
View PDFchevron_right
R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine
Mark Tricklebank
British Journal of Pharmacology, 1991
View PDFchevron_right
Dopaminergic stabilizers for the treatment of schizophrenia. Rat studies focusing on negative symptoms and mechanisms of action
Johan Rung
View PDFchevron_right
Cross interaction of dopaminergic and adrenergic systems in neural modulation
Saobo Lei
2014
View PDFchevron_right
Regulation of Cortical Functions by the Central Noradrenergic System: Emerging Properties from an Old Friend
marco atzori
Monoaminergic Modulation of Cortical Excitability, 2007
View PDFchevron_right
Effect of chronic antidepressant treatment on noradrenergic modulation of [3H]dopamine release from rat nucleus accumbens and striatal slices
B Nurse
Brain Research, 1987
View PDFchevron_right
Effects of Dopaminergic Drugs on the Sympathoadrenal System
Christine Damase-michel
Hypertension Research, 1995
View PDFchevron_right
A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain
Annica Dahlström
Psychopharmacologia, 1975
View PDFchevron_right